LPX TI641
Alternative Names: LPX-TI-641Latest Information Update: 27 Jul 2026
At a glance
- Originator LAPIX Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action Hepatitis A virus cellular receptor 2 agonists; TIMD4 protein agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis; Multiple sclerosis; Myelin oligodendrocyte glycoprotein antibody-associated disease; Neuromyelitis optica; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis